Skip to main content
About
Company Profile
Management Team
Board of Directors
Science
Overview
CD47
STING
Discovery
Pipeline
Overview
TTI-621
TTI-622
TTI-10001 (STING Agonist)
For Patients
Overview
TTI-621-01
TTI-621-02
TTI-622-01
Investors
Contact
Contact Information
Careers
Menu
Investors
Stock Information
Stock Quote & Chart
Historical Price Lookup
Analyst Coverage
Financial Information
SEC Filings
Financial Reports
Corporate Governance
Management Team
Board of Directors
Governance Documents
2019 Annual Meeting
Press Releases
Events & Presentations
Investor Resources
Contact Investor Relations
FAQs
Email Alerts
RSS
Normal
Press Release RSS Feed (opens in new window)
Press Releases
Press release year list
2020
2019
2018
2017
2016
2015
2014
2013
Trillium Announces Pricing of US$101,700,000 Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
January 23, 2020
Download
PDF format download (opens in new window)
Trillium Announces Proposed Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
January 22, 2020
Download
PDF format download (opens in new window)
Trillium Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
January 16, 2020
Download
PDF format download (opens in new window)
Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs
January 7, 2020
Download
PDF format download (opens in new window)